J&J unit buys diagnostics company; Gleevec linked to muscle damage;

> Aiming to strengthen its Ortho-Clinical Diagnostics business, Johnson & Johson said its Nordic AB unit bought Sweden's Amic, which develops technology for faster diagnostic tests, for an undiclosed amount. Report

> French doctors reported a possible new side effect--muscle damage--associated with the Novartis cancer drug Gleevec (imatinib), used to treat chronic myeloid leukemia and gastrointestinal tumors. Report

> FDA approved an implantable medical device tested about five years ago on actor Christopher Reeve to help him breathe without a ventilator. Report

> Watson Pharmaceuticals  spent more than $295,000 lobbying for an approval pathway for generic biologic drugs during the first quarter. Report

> FDA told companies selling fraudulent cancer treatments--such as Tumorex and Breast Cancer Tea--to stop asserting that their products will work like drugs or face seizures, and possibly criminal charges. Report

> Cholesterol-lowering statins may prevent emergency Caesarean sections, researchers found, because high cholesterol weakens contractions. Report

> Theratechnologies is heralding positive Phase III data for its lead program--tesamorelin--for HIV-associated lipodystrophy. Report

> Merck Serono has signed up with Bionomics in a quest to develop new therapies for multiple sclerosis. Report

> J&J's Centocor won a key vote by an FDA expert committee backing the approval of ustekinumab for severe to moderate psoriasis. Report 

Live from BIO 2008

> Biotech has a bright future, but there are challenges ahead. Report

> Governor Arnold dropped by BIO yesterday to promote California's biotech industry. Photo slideshow

And Finally... Brighter Lighting led to clearer thinking in dementia patients, a study found. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.